Table 2. Studies employing empiric SBRT.
| Study | Number of patients | Dose | Inoperable (%) | Biopsy attempted (%) | Median tumor diameter (mm) | Toxicity | 3-year LC, PFS, OS (%) |
|---|---|---|---|---|---|---|---|
| Sakanaka et al. (27) | 37 | 48 Gy/4 fx | 70 | 67 | 20 [7–42] | Gr 2 radiation pneumonitis (RP): 5.4%; rib fracture (RF): 2.7% |
94, 68.6, 74.2 |
| Yoshitake et al. (30) | 88 | 48 Gy/4 fx | 77 | NR | 19 [8–40] | Gr 2 RP: 2.3%; Gr 2 RF: 6.8% | 90, 67, 80 |
| Inoue et al. (26) | 115 | 30–70 Gy/2–10 fx | 62 | 51 | 20 [5–45] | Gr 2: 8.8%; Gr 3: 5.3%; Gr 5: 1.8%* | ≤20 mm/>20 mm: 97/95, NR/NR, 90/61 |
| Harkenrider et al. (31) | 34 | 30–55 Gy/3–10 fx | 100 | 18 | 16 [5–33] | Gr 3–4 dyspnea: 8.8% | 90, NR, 85 (2-year) |
| Wang et al. (32) | 25 | Individualized, median BED 136 Gy | 92 | 0 | NR (68% T1b, 32% T1a) | Gr 3: pneumonitis 8%; Gr 1–2: fatigue 20%, pneumonitis 8% |
78.8, 66.3, 70.2 |
| Studies incorporating tumors pathologically-confirmed (PC) and clinically diagnosed (CD) | |||||||
| Takeda et al. (29) | 398 (115 PD and 58 CD) | 40–50 Gy/5 fx | 73 (PD); 88 (CD) | 52% of CD | 28 [5–62] (PD); 26.5 [10–53] |
Gr 2 RP: 16% (PC), 12% (CD); Gr 3 RP: 3% (PC), 9% (CD) |
PD: 80/74/54; CD: 87/71/57 |
| Chang et al. (14) | 22 (ROSEL only 8 PD and 14 CD) | 50–54 Gy/3–4 fx | 0% | NR | 18 | Gr 3 10% | 96/86/93 |
| Verstegen et al. (28) | 591 (209 PD and 382 CD) | 60 Gy/3,5,8 fx | 72 (PD); 69 (CD) | NR | 34 [11–80] (PD); 28 [10–53] |
Gr 3 RP: 3%; RF: 2%; Gr 3 chest wall pain: 1% |
PD: 90/80/55; CD: 91/73/53 |
*, worsening of interstitial pneumonitis in a pt with tumor > 2 cm. NR, not reported. SBRT, stereotactic body radiation therapy; LC, local control; PFS, progression-free survival; OS, overall survival; PD, pathologic diagnosis.